Search company, investor...

Total Raised

$6.4M

Investors Count

5

Deal Terms

1

Funding, Valuation & Revenue

2 Fundings

Elara Pharmaceuticals has raised $6.4M over 2 rounds.

Elara Pharmaceuticals's latest funding round was a Grant for $2.7M on November 16, 2009.

Elara Pharmaceuticals's valuation in November 2009 was $11.44M.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

11/16/2009

Grant

$2.7M

$99M

0

FY undefined

11/12/2009

Series A

$99M

$11.44M

0

FY undefined

0

Date

11/16/2009

11/12/2009

Round

Grant

Series A

Amount

$2.7M

$99M

Investors

Valuation

$99M

$11.44M

Revenue

0

FY undefined

0

FY undefined

Sources

0

You're one click away from the most comprehensive, unmatched analyst expertise in tech, in-depth private company data and a platform that brings it all together.
Click Now. Join a live demo
Join a demo
CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo

Elara Pharmaceuticals Deal Terms

1 Deal Term

Elara Pharmaceuticals's deal structure is available for 1 funding round, including their Series A from November 12, 2009.

Round

Series A

Funding Date

$99M

Pre-Money Valuation

Post-Money Valuation

Amount Raised

$99M

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

$99M

Board Voting

$99M

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Series A

$99M

$99M

$99M

$99M

Elara Pharmaceuticals Investors

5 Investors

Elara Pharmaceuticals has 5 investors. BMBF GOBio invested in Elara Pharmaceuticals's Grant funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

11/16/2009

11/16/2009

1
Grant

Germany

00/00/0000

00/00/0000

BioRN - Biotechnologie Rhein-Neckar

Subscribe to see more

Other

Germany

00/00/0000

00/00/0000

KfW

Subscribe to see more

Diversified Financial Services

Germany

00/00/0000

00/00/0000

EMBL Ventures

Subscribe to see more

Venture Capital

Germany

00/00/0000

00/00/0000

Wagnisfinanzierungsgesellschaft fuer Technologiefoerderung in Rheinland-Pfalz

Subscribe to see more

Venture Capital

Germany

First funding

11/16/2009

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Last Funding

11/16/2009

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Investor

BioRN - Biotechnologie Rhein-Neckar

KfW

EMBL Ventures

Wagnisfinanzierungsgesellschaft fuer Technologiefoerderung in Rheinland-Pfalz

Rounds

1
Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Board Seats

Type

Other

Diversified Financial Services

Venture Capital

Venture Capital

Location

Germany

Germany

Germany

Germany

Germany

CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo

Compare Elara Pharmaceuticals to Competitors

I
Inflazyme Pharmaceuticals

Inflazyme Pharmaceuticals is a biopharmaceutical company engaged in the discovery, development and commercialization of therapies for the treatment of respiratory and inflammatory diseases. The company's core focus is medicinal chemistry based, orally active, small molecules aimed at treating unmet medical needs.

Longevica Logo
Longevica

Longevica is a biotechnology that is researching mechanisms of healthy aging and life extension. The company is also developing an open research tool for scientists and research institutions to access a data set that tracks the effects of pharmacological compounds for testing drugs.

A
Affibody

Affibody is a private clinical-stage biotech company. It specializes in the discovery of antibody mimetics that provide biodistribution flexibility, tissue penetration, and tumor targeting. The company was founded in 1998 and is based in Solna, Sweden.

S
Sound Pharmaceuticals

Sound Pharmaceuticals (SPI) is a biopharmaceutical company that develops prescription drugs that will enable doctors and patients to prevent and treat hearing loss, a disease that affects over 30 to 40 million Americans. It was founded in 2002 and is based in Seattle, Washington.

B
Bikam Pharmaceuticals

BIKAM Pharmaceuticals, Inc. is an early stage biopharmaceutical company focusing upon the discovery and development of small molecule therapeutics for the treatment of ophthalmic diseases and disorders, including retinitis pigmentosa. Worldwide, there are approximately 1.5 million people which suffer from retinitis pigmentosa (RP), a hereditary disease which leads to blindness. As its initial priority, the company is pursuing the discovery of compounds based on a novel mechanism of action identified by the company's founder, Dr. Shalesh Kaushal. BIKAM has an experienced management team with a strong track record in pharmaceutical drug discovery dedicated to expanding these findings and others from the Kaushal lab to create potential therapeutics to prevent blindness.

G
Greenovation Biotech

greenovation Biotech GmbH is engaged in the production of pharmaceutically highly-efficient glycoproteins

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.